Tests a stem cell transplant regimen with fludarabine in multiple sclerosis
Tests fludarabine with a stem cell transplant in adults with multiple sclerosis.
Plain-language title generated from the registry record
Registry title: AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis
Key facts
- Where
- Saint Petersburg, RussiaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT05832515, who can take part
Where in Russia
- First Pavlov State Medical University of St. PetersburgSaint Petersburg, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- St. Petersburg State Pavlov Medical University
- Trial code
- NCT05832515
- Record updated
- 7 May 2024
- Original description
One of the possible options for the treatment of MS at present is a high-dose immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation (HIST-AHSCT), which is a highly effective treatment for patients with relapsing-remitting MS.Read full original descriptionShow less
Trial of the Efficacy and Safety of High-dose Immunosuppressive Therapy Based on Fludarabine and Cyclophosphamide-containing Conditioning Regimen Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Sclerosis.
One of the possible options for the treatment of MS at present is a high-dose immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation (HIST-AHSCT), which is a highly effective treatment for patients with relapsing-remitting MS.
This method of MS treatment was introduced in 1997. Significant complications and mortality associated with HIST-ATHSC is an obstacle to broad use of this method. The risk is even greater in patients with advanced disease, long duration of previous treatment and aggressive forms of MS.
Despite toxicity certain progressive cases of MS are still an indication for HIST-autoHSCT.
Most commonly used conditioning regimens for multiple sclerosis include high-dose cyclophosphamide. One of the options to reduce cyclophosphamide-related toxicity and dose is addition of fludarabine. Fludarabine is a cytostatic drug, an antimetabolite from the group of purine antagonists. It has a pronounced immunosuppressive activity and no overlapping toxicity with cyclophosphamide. The study will evaluate the safety and efficacy of this combination.
Inclusion: Age 18-65; 1.0-6.5 points on the EDSS scale (for MS); Length of illness - any; Disease progression during the last 6 months while taking drugs of 1st and 2nd lines; An established and confirmed diagnosis of an autoimmune disease in the previous stages of treatment; Ineffectiveness, inaccessibility or intolerance of Disease-Modifying Therapies; Relapse after AHSCT; Absence of severe concomitant somatic pathology; Left ventricular injection fraction > 50%; Karnofsky Performance Score (KPS) > 30%; The ability to take oral medications; Life expectancy is more than 1 month; Signed informed consent of the patient or legal representatives.
Exclusion: Uncontrolled bacterial or fungal infection at the time of enrollment; Somatic or psychiatric disorder making the patient unable to sign informed consent; Moderate or severe cardiac dysfunction, left ventricular ejection fraction <50%; Severe organ dysfunction: AST or ALT >5 upper normal limits, bilirubin >1.5 upper normal limits, creatinine >2 upper normal limits; Creatinine clearance < 60 mL/min; Moderate or severe decrease in pulmonary function, FEV1 <70% or DLCO<70% of predicted; Respiratory distress >grade I; Requirement for vasopressor support at the time of enrollment; Karnofsky performans status <30%; Pregnancy.